introduct
prognosi
enteropathyassoci
cell
lymphoma
poor
predictor
surviv
remain
illdefin
clinic
present
patholog
featur
therapi
influenc
outcom
evalu
thoroughli
character
patient
celiac
diseas
tcell
lymphoma
patient
method
medic
file
studi
retrospect
lymphoma
intestin
mucosa
analys
histopatholog
multiplex
pcr
intestin
intraepitheli
lymphocyt
phenotyp
surviv
prognost
factor
analys
use
kaplanmei
curv
logrank
test
cox
model
result
lymphoma
complic
non
clonal
enteropathi
celiac
diseas
n
type
refractori
celiac
diseas
n
patient
clonal
type
ii
refractori
celiac
diseas
patient
twentyf
patient
underw
surgeri
resect
main
tumour
mass
case
univari
analysi
non
clonal
celiac
diseas
serum
albumin
level
gl
diagnosi
chemotherapi
surgic
resect
predict
good
surviv
p
p
p
p
respect
multivari
analysi
serum
albumin
level
gl
chemotherapi
reduct
surgeri
significantli
associ
increas
surviv
p
p
p
respect
conclus
studi
underlin
prognost
valu
celiac
diseas
type
patient
tcell
lymphoma
suggest
combin
nutrit
chemotherapi
reduct
surgeri
may
improv
surviv
enteropathyassoci
cell
lymphoma
eatl
rare
nonhodgkin
lymphoma
poor
prognosi
fiveyear
surviv
estim
mani
patient
eatl
associ
celiac
diseas
cd
refractori
glutenfre
diet
gfd
yet
cd
previous
known
case
half
case
diagnosi
eatl
made
emerg
surgeri
perform
obstruct
perfor
intestin
haemorrhag
appropri
analysi
tissu
specimen
often
lack
emerg
situat
thu
hamper
precis
assess
eatl
phenotyp
associ
enteropathi
criteria
predict
outcom
rare
lymphoma
lack
specif
recent
studi
poor
prognosi
eatl
associ
larg
tumor
mass
elev
level
ldh
c
reactiv
protein
presenc
cd
predictor
multivari
analysi
higher
risk
eatl
report
patient
type
ii
refractori
celiac
diseas
rcdii
develop
clonal
popul
intraepitheli
lymphocyt
iel
abnorm
phenotyp
patient
type
refractori
celiac
diseas
rcdi
polyclon
normal
iel
yet
remain
unknown
whether
type
cd
clonal
rcdii
non
clonal
includ
glutensensit
cd
rcdi
influenc
outcom
eatl
serum
albumin
recent
shown
valuabl
prognosi
tool
rcd
may
perhap
use
predict
outcom
eatl
inasmuch
enteropathyrel
malnutrit
common
obstacl
chemotherapi
whenev
chemotherapi
possibl
chemoresist
anoth
factor
contribut
bad
prognosi
eatl
chop
regimen
wide
use
regimen
previou
studi
indic
overal
median
surviv
month
except
recent
studi
suggest
better
prognosi
patient
undergo
intens
chemotherapi
follow
autolog
stem
cell
transplant
asct
efficaci
therapeut
regimen
remain
poorli
evalu
herein
taken
advantag
larg
seri
well
character
patient
eatl
cd
assess
nutrit
statu
diagnosi
type
cd
therapeut
regimen
includ
chemotherapi
surgeri
might
influenc
outcom
eatl
medic
file
consecut
patient
diagnos
cell
lymphoma
associ
cd
larg
pari
hospit
european
hospit
georg
pompid
hospit
necker
enfantsmalad
saintloui
review
retrospect
ten
patient
exclud
due
uncharacter
cd
diagnost
lymphoprolif
disord
consequ
patient
consid
studi
followedup
januari
april
mean
followup
month
studi
approv
ethic
committe
iled
franc
ii
pari
franc
clinic
data
record
patient
includ
age
sex
symptom
abdomin
pain
diarrhoea
gluten
intak
bodi
mass
index
bmi
result
tomographi
scan
ctscan
positron
emiss
tomographi
scan
petscan
bone
marrow
aspir
biopsi
blood
test
includ
haemoglobin
dosag
serum
albumin
ldh
iga
aga
igg
agg
antigliadin
antibodi
iga
class
endomysi
antibodi
ema
iga
antihuman
tissu
transglutaminas
ttg
antibodi
genotyp
endoscop
evalu
includ
upper
gastrointestin
endoscopi
doubl
balloon
enteroscopi
intestin
biopsi
histolog
assess
minimum
four
intestin
biopsi
andor
surgic
sampl
fix
formalin
embed
paraffin
section
stain
h
e
review
two
expert
pathologist
nb
vv
villou
atrophi
assess
line
oberhub
et
al
modif
marsh
classif
grade
absent
partial
sever
subtotaltot
percentag
iel
number
iel
per
epitheli
cell
establish
well
orient
serial
section
count
least
epitheli
cell
immunohistochemistri
perform
section
paraffin
embed
biopsi
use
antibodi
direct
rabbit
polyclon
ab
mous
monoclon
ab
mous
monoclon
ab
mous
monoclon
ab
mous
monoclon
ab
mous
monoclon
ab
dako
glostrup
denmark
mous
monoclon
ab
thermo
fisher
scientif
fremon
ca
usa
mous
monoclon
antibodi
mous
monoclon
ab
granzym
b
mous
monoclon
ab
novocastra
newcastl
upo
tyne
uk
mous
monoclon
ab
isotyp
immunotech
marseil
franc
aceton
fix
frozen
tissu
section
use
antibodi
direct
coulter
immunotech
cell
scienc
cambridg
threestag
indirect
immunoperoxidas
techniqu
flowcytometri
phenotyp
iel
lamina
propria
lymphocyt
isol
duoden
biopsi
describ
multicolor
stain
lymphocyt
analys
use
bdlsr
use
cellquest
softwar
bectondickinson
perform
describ
molecular
detect
clonal
chain
rearrang
perform
dna
extract
intestin
extraintestin
frozen
specimen
multiplex
polymeras
chain
reaction
pcr
diagnosi
cd
base
type
detect
celiac
specif
antibodi
villou
atrophi
increas
count
iel
normal
diet
patient
classifi
depend
clinic
histolog
respons
gfd
rcd
defin
clinic
relaps
andor
persist
malabsorpt
syndrom
villou
atrophi
one
year
strict
adher
gfd
divid
rcdi
absenc
detect
clonal
duoden
biopsi
iel
normal
phenotyp
convers
rcdii
duoden
biopsi
contain
clonal
chain
rearrang
abnorm
iel
phenotyp
defin
presenc
iel
express
intracellular
formalin
fix
section
iel
lack
surfac
cell
receptor
complex
flow
cytometri
analysi
iel
isol
fresh
biopsi
eatl
classifi
pleomorph
case
tumor
infiltr
polymorph
lymphoid
cell
anaplasticlik
cell
infiltr
made
larg
atyp
cell
eatl
subclassifi
type
ii
line
patholog
featur
stage
perform
accord
ann
arbour
classif
modifi
musshoff
schmidtvollm
reduct
surgeri
refer
remov
main
primari
tumour
mass
continu
data
summar
use
mean
median
appropri
continu
variabl
compar
use
nonparametr
mannwhitney
test
categor
variabl
compar
use
fisher
exact
test
overt
lymphoma
surviv
analys
use
kaplanmei
methodolog
cox
regress
model
use
assess
associ
surviv
covari
multivari
analys
perform
blackward
fashion
enter
variabl
associ
outcom
level
univari
analysi
analys
predict
valu
serum
albumin
level
patient
divid
two
group
valu
either
median
valu
calcul
patient
statist
analys
perform
use
stat
view
version
softwar
p
valu
less
consid
statist
signific
mean
age
patient
diagnosi
year
patient
eatl
diagnos
emerg
surgeri
small
bowel
obstruct
n
periton
due
intestin
perfor
tumour
n
case
abdomin
pain
weight
loss
andor
fever
led
diagnost
investig
surgeri
patient
endoscopi
biopsi
patient
cutan
percutan
biopsi
patient
imageguid
needl
biopsi
patient
one
patient
diagnosi
eatl
made
autopsi
patient
cd
eatl
diagnos
simultan
followup
indic
patient
respons
gfd
case
cd
previous
known
cd
rcdi
rcdii
mean
time
diagnosi
cd
onset
eatl
month
increas
ldh
note
patient
respect
tabl
mean
bmi
anaemia
low
serum
albumin
level
mean
gl
median
gl
observ
patient
respect
factor
combin
attest
sever
malnutrit
major
patient
diagnosi
eatl
tabl
serum
albumin
level
decreas
eatl
develop
rcdii
non
clonal
form
cd
gl
vs
gl
p
tabl
eatl
local
stage
ie
iie
patient
dissemin
iv
patient
primari
locat
eatl
small
bowel
patient
frequent
multifoc
eatl
present
ulcer
andor
strictur
patient
volumin
abdomin
tumour
mass
patient
patient
eatl
develop
skin
preexist
cutanea
rcdii
lesion
present
nodul
ulcer
diffus
erythema
one
patient
eatl
present
volumin
inguin
lymph
node
anoth
one
tumor
splenomegali
bone
marrow
lung
andor
mediastin
lymph
node
liver
main
metastat
locat
diagnosi
petscan
perform
patient
accur
predict
eatl
locat
patient
differ
note
sensit
accord
type
cd
cdrcdi
vs
rcd
patient
ns
six
patient
develop
haemophagocyt
syndrom
descript
eatl
indic
tabl
ii
list
individu
supplementari
tabl
case
diagnosi
eatl
base
evid
massiv
usual
transpariet
tumour
infiltr
small
intestin
macroscop
featur
character
ulcer
patient
infiltr
indur
intestin
wall
andor
nodul
patient
perfor
tumour
note
patient
diagnosi
case
histolog
reveal
infiltr
lymphoma
cell
pleomorph
appear
mix
reactiv
cell
includ
small
lymphocyt
plasma
cell
histiocyt
polynuclear
cell
especi
eosinophil
fig
case
classifi
larg
cell
anaplasticlik
contain
predomin
larg
lymphoid
cell
express
mostli
high
rate
prolif
marker
fig
case
increas
mitot
index
note
well
express
cytotox
marker
tia
andor
granzym
b
posit
marker
detect
frozen
tissu
section
observ
patient
test
express
absent
two
case
eatl
develop
preexist
rcdii
lesion
patient
patient
note
epiderm
iel
lost
larg
dermal
tumour
infiltr
express
observ
eatl
case
associ
non
clonal
enteropathi
cd
rcdi
stain
neg
test
patient
case
marker
express
tumour
cell
frequent
observ
reactiv
small
lymphoid
cell
infiltr
three
patient
diagnosi
eatl
particularli
difficult
either
due
earli
stage
transform
andor
atyp
aspect
fig
one
patient
rcdii
patient
diagnosi
eatl
made
section
mesenter
lymph
node
immunohistochemistri
combin
standard
microscopi
show
zone
infiltr
small
lymphocyt
indic
dissemin
abnorm
rcdii
iel
lymph
node
also
small
foci
medium
larg
size
granzym
b
lymphoid
cell
strongli
express
prolif
marker
attest
transform
eatl
two
case
cd
patient
rcdii
patient
medium
larg
lymphoid
cell
granzym
b
aggreg
togeth
spread
within
two
metrelong
intestin
mucosa
assess
doubl
balloon
enteroscopi
fig
patient
cd
patient
diagnosi
cd
made
simultan
eatl
base
presenc
posit
antibodi
aga
agg
ema
andor
ttg
haplotyp
villou
atrophi
increas
iel
normal
phenotyp
patient
gfd
time
eatl
diagnosi
patient
previous
diagnos
cd
respons
n
n
gfd
intestin
mucosa
distanc
eatl
contain
iel
normal
phenotyp
show
polyclon
tcr
profil
patient
respond
gfd
cd
patient
de
novo
eatl
cd
patient
refractori
gfd
rcdi
group
patient
non
clonal
enteropathi
villou
atrophi
partial
sever
subtot
total
n
n
patient
respect
except
de
novo
eatl
one
known
cd
patient
patient
strict
gfd
ascertain
dietician
mean
time
month
patient
rcdii
character
expans
abnorm
iel
contain
intracellular
surfac
cell
receptor
complex
gener
weak
clonal
rearrang
gamma
chain
tcr
detect
duoden
biopsi
tabl
rcdii
patient
patient
frozen
specimen
eatl
duoden
mucosa
distanc
eatl
avail
molecular
analysi
demonstr
chain
rearrang
supplementari
tabl
detect
flow
cytometri
freshli
isol
rcdii
iel
patient
detect
immunohistochemistri
tissu
section
correspond
eatl
twentyf
patient
oper
mainli
emerg
tumour
resect
patient
surgic
procedur
describ
patient
tabl
thirtyon
patient
receiv
least
one
cycl
chemotherapi
patient
treat
sever
line
five
patient
could
receiv
chemotherapi
due
uncontrol
gastrointestin
haemorrhag
postop
cardiopulmonari
arrest
sever
acut
respiratori
syndrom
number
patient
treat
sever
line
chemotherapi
lower
patient
eatl
rcdii
patient
eatl
gluten
free
dietrespons
cd
rcdi
although
differ
reach
statist
signific
chemotherapi
base
anthracyclinecontain
regimen
n
mainli
chop
cytarabin
andor
etopesidecontain
treatment
n
tabl
supplementari
tabl
ii
allogen
allosct
autolog
asct
stem
cell
transplant
intensif
perform
three
two
patient
respect
two
three
patient
treat
intensif
allosct
still
aliv
latest
followup
patient
one
patient
treat
palli
radiotherapi
relaps
skin
lesion
eatl
twentyseven
patient
die
followup
median
overal
surviv
month
two
fiveyear
overal
surviv
rate
respect
concern
type
cd
fiveyear
surviv
rate
eatl
complic
non
clonal
cd
gfd
respons
cd
rcdi
eatl
associ
clonal
rcdii
fig
strike
differ
prognosi
observ
patient
differenti
serum
albumin
level
five
year
surviv
rate
patient
serum
albumin
level
superior
gl
diagnosi
null
patient
level
gl
fig
univari
analysi
type
cd
serum
albumin
level
realiz
least
one
cycl
chemotherapi
surprisingli
surgic
tumour
resect
predictor
overal
surviv
fig
neither
diseas
stage
local
versu
dissemin
type
lymphoma
pleomorph
versu
anaplast
predict
overal
surviv
multivari
analysi
serum
albumin
level
gl
treatment
least
one
cycl
chemotherapi
reduct
surgeri
remain
good
prognost
factor
fig
main
caus
mortal
tumour
progress
combin
malnutrit
n
infect
n
facilit
chemotherapyinduc
neutropenia
n
uncontrol
gastrointestin
haemorrhag
n
periton
n
lethal
thrombosi
n
seri
report
case
eatl
associ
cd
confirm
bad
prognosi
show
five
year
surviv
rate
close
previous
report
data
howev
reveal
new
factor
impact
surviv
cd
type
serum
albumin
tumour
reduct
surgeri
eatl
recent
subclassifi
two
type
accord
patholog
genet
featur
type
eatl
gener
associ
cd
phenotyp
type
ii
eatl
gener
associ
cd
phenotyp
present
studi
eatl
associ
cd
compos
pleomorph
cell
andor
contain
larg
anaplasticlik
lymphoma
cell
strongli
posit
none
express
may
thu
classifi
eatl
type
whether
lack
characterist
type
eatl
unclear
recent
studi
report
type
eatl
detect
express
natur
killer
marker
paraffin
section
interestingli
detect
flow
cytometri
abnorm
iel
two
rcdii
patient
correspond
lymphoma
thu
exclud
lymphoma
cell
express
low
level
detect
immunohistochemistri
confirm
previou
studi
observ
cdassoci
eatl
express
ielspecif
integrin
previous
suggest
characterist
well
clonal
filiat
rcdii
iel
eatl
demonstr
herein
case
analysi
chain
rearrang
point
origin
iel
compart
howev
detect
two
case
eatl
develop
skin
mesenter
lymph
node
rcdii
patient
respect
sinc
clonal
rearrang
detect
rcdii
iel
eatl
patient
loss
may
result
either
lack
induct
signal
away
gut
like
dedifferenti
transform
four
eatl
develop
skin
local
rcdii
one
patient
cutan
intestin
lymphoma
develop
simultan
data
point
epitheliotrop
rcdii
eatl
cell
may
favour
bind
ecadherin
express
skin
gut
epitheli
cell
case
patholog
diagnosi
eatl
particularli
arduou
due
lack
massiv
infiltr
tumour
cell
track
abnorm
cytolog
express
mesenter
lymph
node
along
intestin
wall
notabl
case
patient
regular
followup
petscan
allow
detect
enlarg
mesenter
lymph
node
immunohistochemistri
demonstr
presenc
rcdii
iel
also
small
cluster
larg
lymphoma
cell
final
may
note
petscan
particularli
use
eatl
diagnosi
allow
local
tumour
case
whatev
type
cd
studi
stress
interest
precis
defin
type
cd
patient
eatl
thu
univari
analysi
reveal
strike
differ
prognosi
eatl
depend
associ
clonal
non
clonal
cd
fiveyear
surviv
rate
almost
eatl
associ
glutenfre
diet
respons
cd
rcdi
case
associ
rcdii
one
explan
may
lie
fact
clonal
rcdii
iel
alreadi
engag
malign
transform
rcdii
iel
howev
non
prolif
cell
thu
difficult
erad
regular
chemotherapi
may
repres
reservoir
cell
suscept
aggress
transform
second
non
exclus
hypothesi
sever
malnutrit
often
associ
rcdii
yet
low
serum
albumin
level
indic
proteinlos
enteropathi
condit
significantli
associ
rcdii
sever
malnutrit
also
poor
prognosi
valu
furthermor
prognost
valu
low
serum
albumin
level
persist
rcdii
multivari
analysi
fig
suggest
malnutrit
central
poor
prognosi
associ
rcdii
altogeth
data
stress
need
provid
nutrit
support
treat
enteropathi
earli
possibl
improv
toler
chemotherapi
increas
overal
surviv
inde
aggress
treatment
appear
increas
surviv
despit
heterogen
chemotherapi
regimen
possibl
observ
higher
surviv
rate
patient
surgic
resect
chemotherapi
benefit
tumour
reduct
surgeri
might
surpris
gener
consid
first
choic
treatment
lymphoma
yet
observ
signific
posit
impact
debulk
surgeri
overal
surviv
rate
independ
nutrit
statu
encourag
systemat
recours
elect
surgeri
alreadi
advoc
case
metastat
solid
tumour
five
patient
receiv
intens
regimen
chemotherapi
follow
asct
allosct
median
surviv
month
data
keep
recent
scottish
studi
show
high
dosag
ivemtx
chemotherapi
follow
asct
regimen
result
better
surviv
anthracyclinebas
chemotherapi
later
studi
patient
treat
chemotherapi
surgeri
also
better
prognosi
surgeri
may
avoid
complic
chemotherapi
haemorrhag
periton
due
tumour
necrosi
time
surgeri
need
howev
defin
conclus
data
confirm
poor
outcom
eatl
highlight
multidisciplinari
approach
may
improv
prognosi
identifi
underli
enteropathi
delin
nutrit
statu
design
therapeut
strategi
combin
elect
surgeri
intens
chemotherapi
nutrit
support
